Hiberix (Haemophilus Type B Conjugate Vaccine (Tetanus Toxoid Conjugate))

Hiberix is indicated for the prevention of invasive disease caused by Haemophilus influenzae type b. It is used as part of routine childhood immunization schedules and may also be given to older children or adults at risk.

• Primary immunization series in infants (typically at 2, 4, and 6 months of age).
• Booster dose administered after completion of the primary series.
• Immunization of children aged 12–23 months who have not completed the series.
• Use in individuals with certain immunodeficiencies who require protection against Hib.
• Administration to travelers to regions where Hib disease remains endemic.

• The vaccine combines the capsular polysaccharide of Haemophilus influenzae type b with tetanus toxoid protein, creating a conjugate that is recognized by the immune system as a T‑cell dependent antigen. This conjugation enhances B‑cell activation and promotes class‑switching, leading to the production of high‑affinity IgG antibodies that neutralize the Hib polysaccharide and facilitate opsonophagocytic clearance of the bacteria in the bloodstream.

Like most injectable vaccines, Hiberix can cause local and systemic reactions, most of which are mild and self‑limited.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever within 24‑48 hours.
• Irritability or fussiness in infants.
• Mild headache or fatigue.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing or hives.
• High fever (>40 °C) or seizures (febrile convulsions).

Healthcare providers should assess individual risk factors before administering Hiberix and observe patients after vaccination.

• Do not administer to persons with a known severe allergy to any vaccine component.
• Postpone vaccination in individuals with acute moderate or severe illness until recovery.
• Use caution in patients with a history of seizures or febrile convulsions.
• Monitor for signs of anaphylaxis for at least 15 minutes after injection.
• Discuss with a physician before vaccinating immunocompromised patients.
• Consider deferring the vaccine in pregnant women until risk‑benefit is evaluated.

Hiberix has limited known drug interactions, but certain co‑administered agents may require attention.

Avoid

• Live bacterial or viral vaccines administered within 4 weeks (to avoid interference with immune response).

Use with caution

• Immunoglobulin or blood products given within 2 weeks may reduce vaccine efficacy.
• Concomitant administration of other childhood vaccines is generally acceptable but observe for additive local reactions.
• Antipyretics (e.g., acetaminophen) may be used to manage fever but should not be given prophylactically before vaccination.